{"id":"W4221131077","doi":"10.1016/j.lungcan.2022.03.003","title":"Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"United Therapeutics Corporation","keywords":"Irinotecan; Topotecan; Medicine; Tolerability; Internal medicine; Clinical endpoint; Oncology; Lung cancer; Randomized controlled trial; Chemotherapy; Cancer; Adverse effect; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002530989,0.002145802,0.004084206,0.0005078043,0.0007035519,0.001649583,0.001523324,0.001989945,0.008340904],"category_scores_gemma":[0.002071247,0.0009612559,0.003015124,0.0006002388,0.001645233,0.001379075,0.0005945595,0.00527744,0.001181416],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002076876,"about_ca_system_score_gemma":0.002611717,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003751505,"about_ca_topic_score_gemma":0.007854243,"domain_scores_codex":[0.9989433,0.000619287,0.00004241781,0.0001537185,0.00006806824,0.0001732454],"domain_scores_gemma":[0.9983371,0.000539737,0.0002920732,0.0001661543,0.00009586402,0.0005690108],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9891922,0.004174127,0.0002053314,0.0001392604,0.0006828621,0.00001579947,0.00002278687,0.0002685123,0.001023211,0.00007184565,0.0004069759,0.00379701],"study_design_scores_gemma":[0.958862,0.03873343,0.0008551178,0.0000124614,0.0004178418,0.00001475612,0.00001798997,0.0003024096,0.0002489253,0.0001351642,0.0003886458,0.00001139037],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853896,0.00364347,0.000830879,0.000827025,0.001115138,0.003587909,0.001447289,0.0001485567,0.00301013],"genre_scores_gemma":[0.9814719,0.002329182,0.001908414,0.001898358,0.000604058,0.004420915,0.002117998,0.00007036801,0.005178799],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008340904,"threshold_uncertainty_score":0.02790308,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03267758269187104,"score_gpt":0.3941030074496166,"score_spread":0.3614254247577455,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}